Ganirelix
Fast-acting GnRH antagonist that stops premature ovulation during fertility treatment
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Suggested dose
250 mcg
Compound profile
Scientific & efficacy data
Hormone Support
Peptide profile
Strong human trials
Ganirelix
250 mcg · Once daily
Molecular formula
C80H113ClN18O13
- Mol. weight
- 1570.4 g/mol
- CAS number
- 124904-93-4
- PubChem
- 16186314
- Developed · 1995
- Organon/Schering-Plough Research Team
Organon (later Schering-Plough)
Amino acid sequence
Ac-D-2-Nal-D-4-Cl-Phe-D-3-Pal-Ser-Tyr-D-Arg-Leu-Arg-Pro-Gly-NH2Ovulation Control
Allows doctors to control exactly when ovulation happens
IVF Success Improvement
Improves success rates in IVF cycles
Safety & OHSS Prevention
Prevents premature LH surge that can ruin egg quality
Dosing
How much do I take?
250 mcg · once daily during the mid-to-late follicular phase
250 mcg
Once daily during the mid-to-late follicular phase
Covers timing · dose-adjustment guidance.
Suitability
Is this right for me?
Best for improving ivf or icsi success rates & preventing premature ovulation during egg retrieval cycles
Best for
Improving IVF or ICSI success rates
Ganirelix is particularly well-suited for individuals focused on improving ivf or icsi success rates. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Preventing premature ovulation during egg retrieval cycles
Ganirelix is particularly well-suited for individuals focused on preventing premature ovulation during egg retrieval cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Controlling ovarian stimulation in women with unpredictable cycles
Ganirelix is particularly well-suited for individuals focused on controlling ovarian stimulation in women with unpredictable cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Ganirelix with similar peptides to find the best fit for your goals.
Administration
How do I use it?
Subcutaneous injection
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Covers reconstitution · step-by-step technique · storage · a sample daily schedule.
Safety
Is it safe?
7 common side effects · 2 serious
Ganirelix carries an excellent safety record from over 10,000 patients in FDA approval trials and 25+ years of clinical fertility practice.
The antagonist mechanism avoids the flare effect seen with GnRH agonists, making it safer for women with diminished ovarian reserve. Injection site reactions are the most common issue (20-40% of patients), though typically mild bruising rather than systemic toxicity.
The rapid 1-2 hour onset and quick clearance mean side effects resolve quickly if dosing is adjusted.
Ganirelix safety is well-established through Phase 3 multicenter trials (Organon studies, 1995-1999) and post-marketing surveillance of over 250,000 treatment cycles. ASRM and ESHRE guidelines recommend it as a standard first-line antagonist for IVF cycles based on efficacy and tolerability data.
Pivotal trials showed no clinically significant abnormalities in liver, kidney, or hematologic parameters even with daily dosing for 2+ weeks.
Common side effects · experienced by some users
Mild discomfort at treatment site
Some users experience mild discomfort, which is among the most commonly reported effects with Ganirelix. This typically resolves within a few days as the body adjusts.
Management: Apply ice if needed. Rotate treatment sites. These symptoms typically improve within the first week of use.
Injection site reactions (redness, bruising, swelling)
Affects 20-40% of IVF patients using ganirelix. Subcutaneous injections commonly cause localized redness, bruising, or mild swelling that peaks at 24 hours and resolves within 3-5 days. Bruising is more common with repeated daily injections at similar sites. Reactions are typically mild and do not require treatment discontinuation.
Management: Rotate injection sites daily between abdomen and thighs. Apply ice immediately after injection to reduce bruising. Avoid injecting in bruised areas. Use proper subcutaneous technique to minimize tissue trauma. Pain relief medication is rarely needed but available if desired.
Headaches
Occur in 10-20% of patients, typically mild intensity. Onset is usually within 24-48 hours of first injection. Most resolve by day 5-7 of stimulation. Headaches may be related to dehydration from reduced oral intake or hormonal changes from ovarian stimulation, not ganirelix alone.
Management: Stay well hydrated throughout the stimulation cycle, aiming for 2-3 liters of water daily. Apply cool compresses to forehead or back of neck. Rest in a quiet, dark room if headache is bothersome. Acetaminophen or ibuprofen is safe to use (check with your clinic). Headaches usually improve on their own.
Abdominal pain
Affects 15-25% of patients and is primarily related to ovarian stimulation from FSH, not ganirelix itself. Pain is typically mild to moderate, cramp-like in quality, and centered in the lower abdomen. Increases gradually as follicles grow and usually peaks 1-2 days before egg retrieval. Pain resolves within 24-48 hours after retrieval.
Management: Heat application (heating pad on low setting for 15-20 minutes) often provides relief. Wear comfortable, loose clothing. Avoid strenuous exercise and intercourse. Gentle walking is fine. Over-the-counter pain relievers are usually adequate. Contact your clinic if pain suddenly worsens or is severe, as this could indicate ovarian hyperstimulation.
Pelvic discomfort
Experienced by 10-20% of patients as a sense of heaviness, fullness, or pressure in the pelvic region. Typically mild and related to ovarian enlargement from FSH stimulation. Discomfort may intensify if multiple large follicles develop. Usually resolves within days of egg retrieval as ovaries return to normal size.
Management: Rest when possible. Wear supportive, loose-fitting clothing. Avoid heavy lifting and strenuous activity. Warm baths may ease discomfort. Stay hydrated. Pelvic discomfort is expected and not dangerous unless accompanied by severe pain, which requires immediate clinic contact.
Nausea
Occurs in 5-10% of patients, usually mild and intermittent. Onset is typically within 24-48 hours of starting ganirelix. Nausea may be related to hormonal changes, dehydration, or the stress of treatment. Most episodes resolve within days and do not require stopping treatment.
Management: Eat small, frequent meals rather than three large ones. Avoid greasy, fried, or strong-smelling foods. Ginger candies or ginger tea can help settle nausea. Stay hydrated with clear fluids. Take anti-nausea medication only if approved by your clinic, as some medications affect egg quality. Nausea usually resolves spontaneously.
Fatigue or dizziness
Affects 5-10% of patients, typically mild. Fatigue may relate to hormonal fluctuations, sleep disruption from anxiety, or dehydration. Dizziness is usually brief and occurs when standing too quickly or in warm environments. Both typically improve after the first few days as the body adjusts.
Management: Prioritize adequate sleep and rest, aiming for 7-8 hours nightly. Rise slowly from lying or sitting positions to prevent orthostatic dizziness. Stay well hydrated. Avoid excessive heat (hot showers, saunas). Moderate, gentle exercise like walking may help maintain energy. Report persistent severe dizziness to your clinic immediately.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Ganirelix
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Ganirelix should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- Safe:FSH (follicle-stimulating hormone) for egg growth — May be used together under medical guidance.
- Safe:hCG (human chorionic gonadotropin) to trigger final egg maturation — May be used together under medical guidance.
- Safe:GnRH agonists in certain protocol variations — May be used together under medical guidance.
With medications
- Caution:Other GnRH antagonists (like cetrorelix) in the same cycle — Use with caution—discuss with your healthcare provider.
- Caution:Certain herbal supplements that affect hormones — Use with caution—discuss with your healthcare provider.
With supplements
- Safe:Multivitamins — Generally safe to take alongside Ganirelix. Space doses apart if taking oral formulations to ensure optimal absorption.
- Safe:Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
How do I know it's working?
Strong human trials · first signs day 1-4
Evidence level
Strong human trials
(Phase 3 or FDA approved)
Regulatory status
FDA approved for this use
Onset of effects
Moderate
(1-2 weeks)
How it works
Ganirelix works like a lock that prevents the key (GnRH) from opening the door to egg release.
Unlike agonists that initially stimulate before shutting down, ganirelix immediately blocks the GnRH receptors, preventing the LH surge that triggers ovulation. During IVF, this gives doctors precise control over when eggs mature and can be retrieved, dramatically improving success rates.
The deeper mechanism
Ganirelix is a synthetic decapeptide GnRH antagonist with modifications including N-terminal acetylation, D-2-naphthylalanine at position 2, and chlorinated aromatic substitutions that provide competitive antagonism at pituitary GnRH receptors.
Unlike GnRH agonists, ganirelix provides immediate receptor blockade without initial stimulation, achieving suppression of LH and FSH within hours.
During controlled ovarian hyperstimulation, ganirelix prevents premature LH surge (which would trigger ovulation prematurely), allowing synchronized egg maturation.
The drug is administered daily via subcutaneous injection starting mid-cycle, with onset within 1-2 hours and offset within 24 hours of the final dose.
This reversible antagonism provides precise control critical for IVF cycle synchronization, enabling predictable timing of oocyte retrieval and significantly improving fertilization and implantation rates.
What to expect
Day 1-4
What you might notice
- Start FSH injections to stimulate egg growth
- Not yet started
What's normal
- Initial response to Ganirelix is beginning at the cellular level
- Different individuals experience Ganirelix's onset at different rates
- Transient systemic effects from initial Ganirelix exposure are common
What's next
- Maintain consistent Ganirelix administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Day 5-6
What you might notice
- When leading follicle reaches 14mm, start daily ganirelix injections
- Begin 250 mcg once daily
What's normal
- Ganirelix is achieving sufficient receptor engagement
- Initial mechanism of Ganirelix is taking effect
- Early transient effects from Ganirelix administration are resolving
What's next
- Maintain consistent Ganirelix administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Day 7-12
What you might notice
- Continue both FSH and ganirelix, with frequent monitoring via ultrasound
- Continue same dose unless adjusted by doctor
What's normal
- Ganirelix is achieving sufficient receptor engagement
- Initial mechanism of Ganirelix is taking effect
- Early transient effects from Ganirelix administration are resolving
What's next
- Maintain consistent Ganirelix administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Day 10-14
What you might notice
- When 2-3 follicles reach 18mm, receive hCG trigger shot to finalize egg maturation
- Take final dose same evening as trigger
What's normal
- Ganirelix is achieving sufficient receptor engagement
- Initial mechanism of Ganirelix is taking effect
- Early transient effects from Ganirelix administration are resolving
What's next
- Maintain consistent Ganirelix administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Day 11-15
What you might notice
- Egg retrieval procedure 34-36 hours after hCG trigger
- Stopped - cycle complete
What's normal
- Ganirelix response patterns are emerging
- Initial Ganirelix response is consistent with mechanism expectations
- Early tolerance development to Ganirelix is not expected
What's next
- Assess whether Ganirelix response aligns with expectations
- Plan next steps based on initial Ganirelix tolerance and response
- Establish baseline monitoring for Ganirelix response tracking
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Ganirelix over time
- Reduction in symptom frequency or severity
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
Key research
Clinical trials
Tested in people
97 registered studies, 9 still enrolling.
By phase
A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.
What kind of research
About 15,296 people took part in the studies that actually administered Ganirelix. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.
Most recent
Is the Diurnal Variation in Circulating Levels of Cortisol Reflected in Follicular Fluid of Preovulatory Follicles Close to Ovulation?
ART Fertility Clinics LLC
IVF Outcomes With Time-Lapse Culture: Comparison Between PPOS and GnRH Antagonist Protocols
Hanoi Medical University
hCG Priming in Women With Diminished Ovarian Reserve
Kristine Loessl
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Ganirelix is named as an intervention; studies that only mention it in passing are not.
Questions
Frequently asked
How fast does ganirelix work?
Ganirelix starts suppressing LH levels within 1-2 hours of injection. Full suppression is achieved within 24 hours, making it much faster than GnRH agonists that can take 2-3 weeks to work.
Why is blocking LH so important for IVF?
Your body naturally releases eggs on its own schedule through an LH surge. In IVF, doctors need to control the timing to retrieve mature eggs. Without ganirelix, the LH surge would release eggs before they're optimally mature, ruining the cycle. Ganirelix gives doctors complete control.
How is ganirelix different from cetrorelix?
Both are GnRH antagonists, but studies show cetrorelix may provide slightly better LH suppression and lower OHSS risk, while ganirelix works equally well for most patients and may be faster-acting for some. Your doctor chooses based on your situation.
Are the injections painful?
Most patients describe them as relatively painless since they're small needles used for subcutaneous (under the skin) injection. However, repeated injections can cause bruising. Rotating sites and using ice can minimize discomfort.
Can ganirelix affect pregnancy if I'm already pregnant?
Ganirelix should NOT be used if you're pregnant or suspect you are. Always do a pregnancy test before starting a new IVF cycle. If you become pregnant during treatment, stop immediately and contact your doctor.
What happens if I miss a dose?
Take the missed dose as soon as you remember, unless it's almost time for your next dose. Missing a single dose might allow an LH surge, potentially compromising that cycle. Call your fertility clinic immediately if you miss a dose.
Can I use ganirelix at home?
Yes! Ganirelix comes in a pre-filled syringe that's easy to self-inject at home. Most patients inject into the abdomen or thigh. Your fertility clinic will teach you the technique before your cycle starts.
How many eggs does ganirelix help retrieve?
Ganirelix doesn't determine egg quantity - FSH does that. Ganirelix's job is preventing premature ovulation so those eggs can be retrieved when ready. Studies show it helps increase the percentage of mature eggs (which improves quality).
Further reading
History & related research
History · since 1999
The hormone brake for baby-making breakthroughs
A small protein hormone that stops the body from releasing eggs too early during fertility treatment. It gives doctors perfect timing control for IVF.
Read the full history of GanirelixReady for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Ganirelix, on one page.